Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Herstal – page 67

1 407 clinical trials in Herstal, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Herstal at a glance
1 407
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 407 trials in Herstal

Open in trial search

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Bladder cancer

Not recruiting

Study on the Effectiveness of Mistletoe Extract and Mitomycin in Patients with Superficial Bladder Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Abnoba GmbH

Study on Allogeneic Stem Cell Transplantation for Children and Adolescents with Acute Lymphoblastic Leukemia Using Etoposide, Treosulfan, and Thiotepa

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Study of cabozantinib with atezolizumab compared to sorafenib in untreated patients with advanced liver cancer (hepatocellular carcinoma)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Exelixis Inc.

Study Comparing ARI-0001 and Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Axicabtagene Ciloleucel
  • Sponsor:Universitair Medisch Centrum Groningen

Myasthenia gravis

Not recruiting

Study of Telitacicept for Treating Generalized Myasthenia Gravis in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Vor Biopharma Inc.

IgA nephropathy

Not recruiting

Phase 3 Study of Zigakibart (BION-1301) in Adults with IgA Nephropathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MK-3508 in Healthy Participants for RSV Infection

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:MK-3508
  • Sponsor:Merck Sharp & Dohme LLC

Study on Estriol Vaginal Ring for Treating Vaginal Atrophy in Postmenopausal Women

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Estriol
  • Sponsor:SocraTec R&D Concepts in Drug Research and Development GmbH

Study on the Safety and Tolerability of WVE-006 for Patients with Alpha-1 Antitrypsin Deficiency (AATD) Pi*ZZ

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:WVE-006
  • Sponsor:Wave Life Sciences Ireland Limited

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Herstal

What the registry says about research in the country

01 Immune System Diseases

Clinical research in Herstal is focused on immune system diseases, with all currently listed studies centered on atopic dermatitis. These trials are examining whether a new treatment approach can better control symptoms and improve everyday skin health for people living with moderate-to-severe disease.

  • Testing a new therapy for better control of atopic dermatitis
  • Comparing treatment effectiveness against placebo
  • Assessing improvements in skin signs and symptom severity

The research program in this Belgian city is aimed at understanding how well treatment options work for patients who need stronger support than standard care alone.

02 Atopic Dermatitis

The main disease under study is atopic dermatitis, a chronic inflammatory skin condition that can cause itching, redness, and discomfort. Current trials are looking at whether a targeted therapy can offer meaningful relief, either on its own or alongside common skin treatments.

  • Evaluating a new option for moderate-to-severe atopic dermatitis
  • Studying treatment used with topical corticosteroids and topical calcineurin inhibitors
  • Measuring changes in disease control and visible skin improvement
  • Supportive research for patients seeking better symptom management

These studies are designed to help clarify whether newer approaches can improve outcomes for people whose skin disease remains difficult to manage.

03 Topical Combination Treatment Research

Another important area of research is the use of topical corticosteroids and topical calcineurin inhibitors alongside investigational therapy. This work is focused on evaluating how combination treatment may improve relief and disease control compared with standard topical care alone.

  • Studying combination care for moderate-to-severe atopic dermatitis
  • Assessing whether added therapy improves overall response
  • Looking at clinical signs and severity over time

The trials in Belgium reflect a practical clinical question: whether pairing new and established treatments can lead to better outcomes for patients.

04 Therapeutic Innovation in Skin Inflammation

The local trial landscape is small but concentrated, with all active studies exploring a single inflammatory skin condition. This makes Herstal a focused site for research on newer therapies aimed at reducing the burden of persistent eczema symptoms.

  • Exploring a new treatment for inflammatory skin disease
  • Comparing benefit against standard control approaches
  • Helping define better options for routine patient care

Overall, the studies are centered on improving treatment effectiveness and expanding options for people living with difficult-to-treat skin inflammation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.